GSK Management

Management criteria checks 2/4

GSK's CEO is Luke Miels, appointed in Jan 2026, has a tenure of less than a year. directly owns 0.007% of the company’s shares, worth $7.37M. The average tenure of the management team and the board of directors is 3.5 years and 3.8 years respectively.

Key information

Luke Miels

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.007%
Management average tenure	3.5yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

Seeking Alpha • May 25

GSK: Improved Prospects After Correction

Summary While GSK was in fine form when I last checked on it in March, it was fairly priced for the short term. With a small price correction since, however, it looks good even for the near term, padded by increased dividends and ongoing share repurchases. Its financials, as evident in the Q1 2026 results, are also in order. And the two latest acquisitions are unlikely to cause any strain on the company's financials either. Read the full article on Seeking Alpha

Seeking Alpha • Feb 18

GSK's Strong Performance: Why I'm Upgrading To 'Strong Buy'

Summary GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the fourth quarter of 2024, more than tripling year-on-year. While sales of the HIV therapy called Cabenuva also did not disappoint, totaling $396 million, up 23.8% quarter-on-quarter. GSK also raised its 2031 sales outlook to £40 billion from £38 billion. In this article, you will learn about other reasons why I am upgrading GSK's rating from 'Buy' to 'Strong Buy.' Read the full article on Seeking Alpha

CEO

Luke Miels (52 yo)

less than a year

Tenure

Mr. Luke Victor Miels has been the Chief Executive Officer & Director at GSK plc and at GlaxoSmithKline LLC since January 01, 2026 and served as its Chief Commercial Officer from September 4, 2017 to Janua...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Julie Brown	CFO & Executive Director	3.2yrs	UK£9.73m	0.0043% $ 4.4m
Emma Walmsley	Executive Officer	less than a year	UK£15.68m	0% $ 0
Jesse Goodman	Scientific & Medical Expert	no data	UK£61.57k	no data
Luke Miels	CEO & Director	less than a year	no data	0.0073% $ 7.4m
Shobie Ramakrishnan	Chief Digital & Technology Officer	5.4yrs	no data	no data
Tony Wood	Chief Scientific Officer and Head of R&D	3.8yrs	no data	no data
Constantin Fest	Senior VP & Head of Investor Relations	no data	no data	no data
James Ford	Senior VP and Group General Counsel of Legal & Compliance	7.8yrs	no data	no data
David Redfern	President of Corporate Development	no data	no data	no data
Roanne Parry	Chief People Officer	less than a year	no data	no data
Philip Thomson	President of Global Affairs	9.2yrs	no data	0.0084% $ 8.6m
Regis Simard	President of Global Supply Chain	no data	no data	no data

3.5yrs

Average Tenure

56yo

Average Age

Experienced Management: GSK's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Julie Brown	CFO & Executive Director	3.1yrs	UK£9.73m	0.0043% $ 4.4m
Luke Miels	CEO & Director	less than a year	no data	0.0073% $ 7.4m
Jonathan Symonds	Chair	6.8yrs	UK£833.00k	0.0023% $ 2.3m
Vishal Sikka	Independent Non-Executive Director	3.9yrs	UK£179.52k	0.00062% $ 630.3k
Hal Barron	Non-Executive Director	8.4yrs	UK£342.73k	0.034% $ 34.4m
Harry Dietz	Independent Non-Executive Director	4.4yrs	UK£210.68k	0.00024% $ 244.0k
Anne Beal	Independent Non-Executive Director	5.1yrs	UK£183.97k	0.00025% $ 254.2k
Wendy Mira Becker	Independent Non-Executive Director	2.7yrs	UK£202.00k	0.00030% $ 305.0k
Charles Bancroft	Senior Independent Non-Executive Director	6.1yrs	UK£262.61k	0.0020% $ 2.1m
Gavin Screaton	Independent Non-Executive Director	1.1yrs	UK£108.00k	0.00038% $ 386.3k
Tsun-Huei Lee	Independent Non-Executive Director	2.3yrs	UK£166.17k	0.000090% $ 91.5k
Elizabeth Anderson	Independent Non-Executive Director	3.8yrs	UK£148.37k	0.00017% $ 172.8k

3.8yrs

Average Tenure

64yo

Average Age

Experienced Board: GSK's board of directors are considered experienced (3.8 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/06/09 18:53
End of Day Share Price	2026/06/09 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GSK plc is covered by 46 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research
Emily Field	Barclays

GSK Management

Management criteria checks 2/4

Key information

Recent management updates

GSK plc, Annual General Meeting, May 06, 2026

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc, Annual General Meeting, May 07, 2025

GSK plc Announces Board and Committee Changes

Recent updates

GlaxoSmithKline LLC entered into an Agreement and Plan of Merger to acquire Nuvalent, Inc. (NasdaqGS:NUVL) for $10 billion.

Sino Biopharmaceutical Limited Presents Data From Two Phase III Clinical Trials Of Bepirovirsen At EASL 2026

GSK PLC Reports Positive Phase 3 Data For Bepirovirsen In Chronic Hepatitis B

GSK: Improved Prospects After Correction

GSK plc to Report Q3, 2026 Results on Oct 28, 2026

Gsk plc Receives Expanded Approval in Japan for Adults Aged 18-59 At Increased Risk

GSK plc Announces Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the US FDA

Gsk plc Receives US FDA Breakthrough Therapy and Ema Priority Medicines (Prime) Designations for Mash

GSK plc to Report Q1, 2026 Results on Apr 29, 2026

GSK plc Announces the National Medical Products Administration of China Has Approved Blenrep (Belantamab Mafodotin) in Combination with Bortezomib and Dexamethasone (BVd) for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma

GSK plc Receives Additional Marketing Approval for Depemokimab

GSK plc (LSE:GSK) completed the acquisition of 35Pharma Inc.

Bioversys Ag Publishes Pre-Clinical Data of Alpe Drug Combination in Nature Communications

GSK plc Announces Exdensur Approval for CRSwNP in China

Samsung Biologics America, Inc completed the acquisition of Human Genome Sciences Inc. from GSK plc (LSE:GSK).

Bepirovirsen Accepted for Regulatory Review in China as A Potential First-In-Class Functional Cure for Chronic Hepatitis B

GSK PLC Bepirovirsen Accepted For Review By The European Medicines Agency As A Potential First-In-Class Treatment For Chronic Hepatitis B

GSK plc, Annual General Meeting, May 06, 2026

US Food and Drug Administration Approves GSK plc's Lynavoy(linerixibat)

GSK plc Announces Expansion of AREXVY Approval to Adults Aged 18 to 49 Years for RSV Prevention

Angeion Group Announces Proposed Settlement in DeCostanzo v. GlaxoSmithKline

GSK plc Appoints Elizabeth McKee Anderson as Member of the Corporate Responsibility Committee, Effective March 9, 2026

GSK plc (LSE:GSK) completed the acquisition of 93.4% stake in RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc Announces That Japan's Ministry of Health, Labour and Welfare Accepts for Review A New Drug Application for Bepirovirsen

GSK plc (LSE:GSK) entered an agreement to acquire 35Pharma Inc for CAD 950 million.

GSK plc Announces New Effectiveness Data for AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) At RSVVW'26

GSK plc's RSV Vaccine Accepts for Review by China's Center for Drug Evaluation for the Prevention of Lower Respiratory Syncytial Virus Disease

GSK plc Announces Nucala (Mepolizumab) Approval by European Commission for Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Gsk Plc's Rsv Vaccine Receives European Approval for Expanded Use in All Adults 18 Years and Older

GSK plc (LSE:GSK) entered a definitive agreement to acquire RAPT Therapeutics, Inc. (NasdaqGM:RAPT) for $1.7 billion.

GSK plc to Report Q4, 2025 Results on Feb 04, 2026

GSK plc Appoints Luke Victor Miels as Director, Effective January 1, 2026

GSK plc Announces Positive Topline Results from B-Well 1 and B-Well 2 Phase 3 Studies for Bepirovirsen

GSK plc Announces the Approval of Exdensur ( Depemokimab) by Japan's Ministry of Health, Labour and Welfare

GSK plc Announces China's National Medical Products Administration Approval of Nucala (Mepolizumab) as Add-On Maintenance Treatment of Adult Patients with Inadequately Controlled COPD

Samsung Biologics America, Inc. entered into a definitive agreement to acquire Human Genome Sciences Inc. from GSK plc (LSE:GSK) for $280 million.

Spero Therapeutics, Inc. Announces Nda Resubmission of Tebipenem Hbr by Gsk to the Fda for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

GSK plc Announces Exdensur (depemokimab) Approved by US FDA for the Treatment of Severe Asthma

GSK plc Announces the Marketing Authorisation of Exdensur ( Depemokimab) by the UK's Medicines and Healthcare Products Regulatory Agency

GSK plc Announces US FDA Approval Of Blujepa For Gonorrhoea Indication

GSK plc Receives Orphan Drug Designation from US Food and Drug Administration for the Treatment of Small-Cell Lung Cancer

GSK plc Upgrades Earnings Guidance for the Year Ending December 31, 2025

GSK plc Announces US FDA Approves Blenrep (Belantamab Mafodotin-Blmf) in Combination with Bortezomib and Dexamethasone (BVd) for Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

GSK plc Announces Positive Phase III Data for Next-Generation Low Carbon Version of Ventolin Metered Dose Inhaler

GSK's Shingrix New Prefilled Syringe Presentation Receives Positive CHMP Opinion

GSK's Shingrix Approved in China for Prevention of Shingles in Adults Aged 18 and over Who are at Increased Risk Due to Immunodeficiency or Immunosuppression

GSK plc to Report Q3, 2025 Results on Oct 29, 2025

GSK plc Announces Major Update to Vaccine Track

US Food and Drug Administration Accepts GSK plc's Gepotidacin as an Oral Option for the Treatment of Unplicated Urogenital Grogenital Grogenital Gonorrhoea

GSK plc Provides Update on US Settlement of CureVac/BioNTech mRNA Patent litigation

GSK plc Declares Second Interim Dividend for Second Quarter of 2025, Payable on 9 October 2025

GSK plc Announces Blenrep (Belantamab Mafodotin) Combinations Approved in EU for Treatment of Relapsed/Refractory Multiple Myeloma

GSK plc Provides Update on US FDA Advisory Committee Review of Blenrep (belantamab Mafodotin-blmf) Combinations

US FDA Accepts Application to Review Expanded Use of GSK's RSV Vaccine, Arexvy, for Adults 18-49 At Increased Risk

GSK plc (LSE:GSK) completed the acquisition of Efimosfermin alfa drug from Boston Pharmaceuticals Inc.

GSK plc Announces FDA Approves Benlysta (belimumab) Autoinjector for Children with Active Lupus Nephritis

Gsk plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Regulatory Application to Expand Use of Gsk's Rsv Vaccine

GSK plc Announces the Linked by Lupus: Optimal Care Initiative to Help Support Individuals with Lupus in the US

GSK plc's RSV Vaccine Accepts for Regulatory Review by the European Medicines Agency to Expand Use in Adults 18 Years and Older

GSK plc announces the US Food and Drug Administration has accepted for review the NDA for linerixibat

GSK plc and Spero Therapeutics Announces PIVOT-PO Phase III Study for Tebipenem HBr Starts Early for Efficacy

GSK plc Announces Blenrep (Belantamab Mafodotin) Combination Receive Positive CHMP Opinion in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Approval Ofenrep Combinations by Japan's Ministry of Health, Labour and Welfare for the Treatment of Adults with Relapsed/Refractory Multiple Myeloma

GSK plc (LSE:GSK) agreed to acquire Efimosfermin alfa drug from Boston Pharmaceuticals Inc. for $2 billion.

GSK plc Announces Positive Results for Nucala

GSK plc Announces the Authorisation of Blenrep by the Medicines and Healthcare Products Regulatory Agency

GSK plc Recommends the Use of RSV Vaccines Including GSK'sAREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted)

GSK plc to Report Q1, 2025 Results on Apr 30, 2025

GSK's Omjjara (Momelotinib) Approves in Singapore as the First Treatment Indicated for Myelofibrosis Patients with Anaemia

GSK plc, Annual General Meeting, May 07, 2025